Cumberland Pharmaceuticals Inc. (CPIX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CPIX Stock Summary
- CPIX has a market capitalization of $33,701,416 -- more than approximately only 10.36% of US stocks.
- The price/operating cash flow metric for CUMBERLAND PHARMACEUTICALS INC is higher than only 22.68% of stocks in our set with a positive cash flow.
- In terms of twelve month growth in earnings before interest and taxes, CUMBERLAND PHARMACEUTICALS INC is reporting a growth rate of 1,508.86%; that's higher than 98.67% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to CUMBERLAND PHARMACEUTICALS INC are BODY, GNRC, MFGP, MIND, and AIN.
- Visit CPIX's SEC page to see the company's official filings. To visit the company's web site, go to www.cumberlandpharma.com.
CPIX Valuation Summary
- CPIX's price/sales ratio is 0.8; this is 83.33% lower than that of the median Healthcare stock.
- Over the past 162 months, CPIX's EV/EBIT ratio has gone down 42.4.
Below are key valuation metrics over time for CPIX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CPIX | 2022-11-25 | 0.8 | 0.8 | -4.7 | -4.7 |
| CPIX | 2022-11-23 | 0.8 | 0.9 | -4.8 | -4.9 |
| CPIX | 2022-11-22 | 0.8 | 0.8 | -4.7 | -4.8 |
| CPIX | 2022-11-21 | 0.8 | 0.9 | -4.8 | -4.9 |
| CPIX | 2022-11-18 | 0.8 | 0.8 | -4.6 | -4.7 |
| CPIX | 2022-11-17 | 0.8 | 0.9 | -4.7 | -4.8 |
CPIX Growth Metrics
- Its 4 year net cashflow from operations growth rate is now at 660.46%.
- The 4 year cash and equivalents growth rate now stands at -21.69%.
- Its year over year net cashflow from operations growth rate is now at -30.19%.
The table below shows CPIX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 41.20713 | 6.775045 | -6.977209 |
| 2022-06-30 | 37.8666 | 4.037711 | -7.623848 |
| 2022-03-31 | 36.62293 | 4.406396 | -5.059668 |
| 2021-12-31 | 35.98504 | 6.342443 | -3.507587 |
| 2021-09-30 | 37.92672 | 5.236684 | -0.543665 |
| 2021-06-30 | 39.10486 | 6.19576 | 0.029876 |
CPIX Price Target
For more insight on analysts targets of CPIX, see our CPIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $8.50 | Average Broker Recommendation | 2 (Hold) |
CPIX Stock Price Chart Interactive Chart >
CPIX Price/Volume Stats
| Current price | $2.27 | 52-week high | $7.51 |
| Prev. close | $2.40 | 52-week low | $1.89 |
| Day low | $2.23 | Volume | 8,900 |
| Day high | $2.34 | Avg. volume | 41,446 |
| 50-day MA | $2.39 | Dividend yield | N/A |
| 200-day MA | $2.43 | Market Cap | 33.28M |
Cumberland Pharmaceuticals Inc. (CPIX) Company Bio
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.
Latest CPIX News From Around the Web
Below are the latest news stories about CUMBERLAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPIX as an investment opportunity.
Cumberland Pharmaceuticals Third Quarter 2022 Earnings: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)Cumberland Pharmaceuticals ( NASDAQ:CPIX ) Third Quarter 2022 Results Key Financial Results Revenue: US$11.4m (up 41... |
Cumberland Pharmaceuticals Reports 41% Revenue GrowthCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million during the third quarter of 2022 - a 41% increase over the prior year period. Cumberland also reported a 19% increase in net revenues for the first nine months of the year compared to the same period in 2021. |
CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWESTCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest, public biopharmaceutical company founded and headquartered in Tennessee, announced today that it has moved its headquarters to the Broadwest campus in the Vanderbilt/West End corridor of Nashville. The company is focused on its mission of advancing patient care through the delivery of high quality medicines. |
Edited Transcript of CPIX.OQ earnings conference call or presentation 9-Aug-22 8:30pm GMTQ2 2022 Cumberland Pharmaceuticals Inc Earnings Call |
Cumberland Pharmaceuticals Reports 14% Revenue GrowthCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $10.3 million during the second quarter of 2022 – a 14% increase over the prior year period. Cumberland also reports a 10% increase in net revenues for the first half of the year compared to the same period in 2021. |
CPIX Price Returns
| 1-mo | -10.31% |
| 3-mo | 1.34% |
| 6-mo | 10.73% |
| 1-year | -44.63% |
| 3-year | -56.64% |
| 5-year | -70.13% |
| YTD | -51.39% |
| 2021 | 58.31% |
| 2020 | -42.72% |
| 2019 | -14.59% |
| 2018 | -18.07% |
| 2017 | 33.82% |
Continue Researching CPIX
Here are a few links from around the web to help you further your research on Cumberland Pharmaceuticals Inc's stock as an investment opportunity:Cumberland Pharmaceuticals Inc (CPIX) Stock Price | Nasdaq
Cumberland Pharmaceuticals Inc (CPIX) Stock Quote, History and News - Yahoo Finance
Cumberland Pharmaceuticals Inc (CPIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...